Schrödinger, Inc. (NASDAQ:SDGR) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET

Company Participants

Jaren Madden - SVP, IR & Corporate Affairs

Ramy Farid - CEO

Geoff Porges - CFO

Karen Akinsanya - President R&D, Therapeutics

Conference Call Participants

Michael Yee - Jefferies

David Lebowitz - Citigroup

Evan Seigerman - BMO Capital Markets

Vikram Purohit - Morgan Stanley

Matt Hewitt - Craig-Hallum

Gaurav Goparaju - Berenberg Capital Markets

Michael Ryskin - Bank of America

Joseph Catanzaro - Piper Sandler

Chris Shibutani - Goldman Sachs

Operator

Thank you for standing by. Welcome to Schrödinger's Conference Call to review Second Quarter 2023 Financial Results. My name is Chris, and I will be your operator for today's call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]. Please be advised that this call is being recorded at the company's request.

Now, I would like to introduce your host for today's conference, Ms. Jaren Madden, Senior Vice President Investor Relations and Corporate Affairs. Please go ahead.

Jaren Madden

Thank you, and good afternoon, everyone. Welcome to today's call during, which we will provide an update on the company and review our second quarter 2023 financial results.

Earlier today, we issued a press release summarizing our financial results and progress across the company, which is available on our website at shordinger.com. Here with me on our call today are Ramy Farid, Chief Executive Officer; Geoff Porges, Chief Financial Officer; and Karen Akinsanya, President of R&D Therapeutics. Following our prepared remarks, we'll open the call for Q&A.

During today's call, management will make statements that are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our outlook for the full-year 2023, our quarter ending September 30, 2023, our plans to accelerate the growth of our software business and advance our collaborative and proprietary drug discovery programs, the timing of initiation of and readouts from our clinical trials, the clinical potential and properties of our compounds, the use of our cash resources as well as our future expenses.

These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially due to a number of important factors, including the considerations described in the Risk Factors section and elsewhere in the filings we make with the SEC, including our Form 10-Q for the quarter ended June 30, 2023. These forward-looking statements represent our views only as of today, and we caution you that except as required by law we may not update them in the future, whether as a result of new information, future events or otherwise.